A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Phase 1 Completed 50 enrolled GlaxoSmithKline

RandomizedSingle-groupSingle-blindTreatment

Summary

A study to investigate the safety and tolerability of both single and multiple intravenous administration of GSK933776 in patients with Alzheimer's Disease.

Timeline

Start: 2007-03-12
Primary completion: 2011-05-30
Completion: 2011-05-30

Publications

Andreasen N, Simeoni M, Ostlund H, Lisjo PI, Fladby T, Loercher AE, Byrne GJ, Murray F, Scott-Stevens PT, Wallin A, Zhang YY, Bronge LH, Zetterberg H, Nordberg AK, Yeo AJ, Khan SA, Hilpert J, Mistry PC. First administration of the Fc-attenuated anti-beta amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. PLoS One. 2015 Mar 19;10(3):e0098153. doi: 10.1371/journal.pone.0098153. eCollection 2015.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GSK933776	Monoclonal antibody	0.001 mg/kg	Intravenous
Subject	GSK933776	Monoclonal antibody	0.01 mg/kg	Intravenous
Subject	GSK933776	Monoclonal antibody	0.1 mg/kg	Intravenous
Subject	GSK933776	Monoclonal antibody	1 mg/kg	Intravenous
Subject	GSK933776	Monoclonal antibody	3 mg/kg	Intravenous
Subject	GSK933776	Monoclonal antibody	10 mg/kg	Intravenous

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

Summary

Timeline

Publications

Drugs

Indications